SLDB Solid Biosciences Inc

$SLDB Back on the 200-day. This one matters. Solid Bio has been bleeding off the July high (~$11.40), and the Sept bounce stalled at a lower high near $10.45. The last two sessions took out the 50-day ($8.91) and 100-day ($8.46). Today it closed at $7.48 (−6.73%), 7 cents under the rising 200-day ($7.55). That 200-day has been the floor since the stock reclaimed it in Dec. It was tested in Jan, Feb, Mar, and May, and every tap got bought. A 7-cent close under it on one day isn't a breakdown. It needs follow-through. Until then it's a test, not a verdict. Tell of the tape: the intraday low was $7.35. S-1 sits at $7.34. Buyers stepped in to the penny. Levels I'm watching: • S-1: $7.00–$7.34, today's low and the first shelf • S-2: $6.00–$6.34, the May retest of the 200-day • S-3: $5.24, the Dec/Jan base Momentum: Stochastics at 12.56 is oversold. RSI at 33.55 is close, but not there. ADX is 21.48 and rising, with −DI at 37.57 against +DI at 13.93. Sellers are in control and the trend is gaining strength. In a small-cap biotech tape, oversold can stay oversold for a while. No capitulation volume either. 1.35M today is not the kind of flush that usually marks a low. Bottom line: a reclaim of $7.55, then $8.00+, and this is just another 200-day hold. If it fails to reclaim, S-1 gives way and $6.00–$6.34 is in play. No position. Just reading the chart. Do your own work.

$SLDB ... this is back in my buying zone for sure..... one of my Gene Therapy bets that have for a long time held various levels of stock in...

$SLDB POLARIS-101 biodistribution → high microdystrophin expression at a relatively low dose → broad biological response → favorable safety → objective + conventional functional measures → FDA totality-of-evidence argument → potential Accelerated Approval. Imho plz do DD!

$SLDB I sold at 6.20 (92% gain) a couple of months ago and thought I would back in at 6.50. Who would have thought...

$SLDB Volatility Expectations: Biotech stocks heading into FDA meetings typically experience increased volume and volatility as institutional position-building occurs in advance of the readout or meeting minutes. Imho